查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1836744

口服蛋白質和多肽市場（按產品類型、配方、藥物開發階段、應用和最終用戶分類）—2025-2032 年全球預測

Oral Proteins & Peptides Market by Product Type, Formulation, Development Stage, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，口服蛋白質和胜肽市場將成長至 192.1 億美元，複合年成長率為 13.67%。

主要市場統計數據
基準年2024年 68.9億美元
預計2025年 77.8億美元
預測年份：2032年 192.1億美元
複合年成長率（%） 13.67%

全面介紹口服蛋白質和胜肽療法如何重新定義整個醫療保健系統的臨床交付模式和商業策略

蛋白質和多肽的口服給藥代表著治療方法的關鍵性變革，它重塑了臨床醫生、患者和行業相關人員對生物製劑治療途徑的認知。最近的技術進步解決了酶分解、上皮滲透性和生物有效性度缺乏一致性等障礙，將曾經只能注射的分子轉變為口服給藥的候選藥物。因此，研發人員正在探索各種配方策略和給藥平台，將化學、設備工程和製劑科學結合，以探索患者偏好的給藥途徑，並擴大生技藥品的治療範圍。

隨著監管格局的日趨成熟，監管機構和支付方越來越關注口服蛋白質和多肽為慢性病管理、癌症支持治療和荷爾蒙療法提案的差異化價值主張。這種轉變正在影響投資重點、合作策略和臨床開發路徑。重要的是，臨床和商業性潛力不僅取決於分子創新，還取決於可擴展的生產、檢驗的藥物動力學性能以及可重複的真實世界依從性結果。這些因素共同構成了一個複雜的生態系統，其中科學前景和商業性可行性必須協調一致。

本執行摘要融合了策略曲折點、細分市場驅動的洞察、區域動態、公司指南和可操作性建議，旨在指導領導者在產品線優先順序、通路開發和製造佈局方面做出具有時效性的決策。本分析著重於可操作性情報和嚴謹方法的透明度，旨在幫助相關人員應對複雜的監管環境、最佳化產品系列，並加速病患在不同醫療環境中的可及性。

極具影響力的科學、監管和商業性曲折點，加速從注射生技藥品到患者首選口服製劑的轉變

在科學、監管和商業性力量融合的推動下，口服蛋白質和胜肽的市場格局正在經歷一系列變化。首先，吸收促進劑、蛋白酶抑制劑和載體技術的進步顯著提高了某些胜肽類的口服生物有效性，使得先前僅限於腸外給藥的分子能夠重新配製用於口服給藥。腸溶衣和奈米顆粒系統以及製劑化學的進步提高了胃腸道穩定性，使長期口服方案更加可行。

同時，法律規範也在不斷發展，以適應新型治療方法和組合藥物。監管機構正在明確生物等效性、安全邊際以及器械-藥物聯合開發的證明途徑，以減少申辦方的不確定性，並透過更早的協調加快開發進度，尤其是在口服給藥已被證明可以提高依從性、減少就診次數並減少注射相關不利事件的情況下。

商業性，相關人員的期望也在改變。患者和醫療保健提供者越來越重視便利性和生活品質，而醫療系統則嚴格審查醫療保健總成本。這些趨勢正在推動專業生物技術公司、合約開發和受託製造廠商以及更廣泛的製藥生態系統之間建立策略夥伴關係，以整合臨床開發、可擴展製造和全球分銷方面的能力。最後，再形成，而有效的患者援助計劃和管道策略將決定最終的贏家和市場動態。

2025 年實施的貿易政策轉變如何推動整個口服生技藥品價值鏈的供應鏈重組、採購多元化和戰略協議

2025年生效的貿易政策調整，為口服蛋白質和多肽製造商和經銷商帶來了新的營運和策略複雜性。關稅變化改變了關鍵投入品的到岸成本，包括輔料、先進配方成分和特殊包裝材料。因此，籌資策略已轉向優先考慮供應商多元化和區域採購，以減少單一國家關稅的影響，並緩解投入品價格波動。

製造商的應對之策是重新評估其全球製造佈局，並加速關於近岸外包和多站點冗餘的討論。這些決策不僅出於成本考慮，還考慮到前置作業時間的可靠性、跨轄區監管的協調性以及持續供應慢性病藥物的需求。隨著企業尋求在不加劇貿易摩擦的情況下實現跨地區靈活的生產能力，對受託製造廠商的需求再次上升。

同時，關稅環境也影響了夥伴關係結構和商業合約。企業擴大將關稅應急條款納入供應商合約和定價模型，一些企業也採取了對沖策略，以保護利潤免受短期貿易中斷的影響。付款人和綜合醫療服務網路也重新調整了採購預期，預測潛在的傳導效應，並尋求風險分擔安排，以穩定病患的就醫管道。

重要的是，關稅加速了對原料標準化和製程最佳化的投資，從而降低了單劑量成本並增強了供應鏈的韌性。一些企業也重新平衡了研發預算，優先考慮製程改善和配方穩健性，從而減少了對稀缺或關稅敏感型投入的依賴。整體而言，2025年關稅的累積影響促使企業採取策略性舉措，轉向供應鏈敏捷性、協同製造模式和合約結構，旨在在更不確定的貿易環境中保持市場進入和價格穩定。

細分主導框架，將產品類型、配方選擇、臨床開發階段、治療用途和最終用戶管道與策略決策連結起來

深入的細分揭示了科學進步與商業性機會的交匯點，使領導者能夠根據患者需求和可行性調整投資和開發重點。根據產品類型，市場分為基於胰島素的蛋白質和胜肽療法。基於胰島素的蛋白質類別包括複合胰島素、長效胰島素類似物、速效胰島素類似物和重組人類胰島素，每種類型都面臨與酵素穩定性和吸收動力學相關的獨特配方和給藥挑戰。胜肽類療法類別包括基於抑鈣素的療法、Glucagon-Like Peptide-1受體促效劑和加壓素類似物，其中分子大小、受體藥理學和目標適應症決定了口服給藥的可行性。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 脂質化和聚乙二醇化技術的進步可提高口服胜肽的穩定性和生物有效性
  • 整合下一代滲透促進劑以增強口服蛋白質藥物的細胞滲透
  • 糖尿病治療中口服胰島素和GLP-1類似物的自乳化藥物傳遞系統的開發
  • 在配方中使用新型蛋白酶抑制劑來保護治療性胜肽免於消化分解
  • 針對微生物組的胜肽療法調節腸道菌叢並提高口服藥物療效的新用途
  • 生技公司與製藥公司之間的策略合作，加速口服胜肽疫苗和療法的商業化
  • 美國和歐盟監管協調努力簡化口服胜肽類候選藥物的核准途徑
  • 應用人工智慧驅動的胜肽工程平台最佳化口服生物有效性並縮短開發時間

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 口服蛋白質和胜肽市場（依產品類型）

  • 胰島素類蛋白質
    • 結合胰島素製劑
    • 長效胰島素類似物
    • 速效胰島素類似物
    • 重組人類胰島素
  • 胜肽療法
    • 以抑鈣素為基礎的治療方法
    • Glucagon-Like Peptide-1受體促效劑
    • 加壓素類似物

9. 口服蛋白質和多胜肽市場（按配方）

  • 膠囊劑型
  • 液體製劑
  • 粉末製劑
  • 片劑配方

第 10 章：口服蛋白質和多胜肽市場（依藥物開發階段）

  • I期和II期臨床試驗
  • III期臨床試驗
  • 上市後監測
  • 臨床前研究

第11章口服蛋白質和多肽市場（按應用）

  • 癌症治療
  • 心血管疾病
  • 糖尿病管理
  • 荷爾蒙失調

第 12 章：口服蛋白質和胜肽市場（按最終用戶）

  • 居家照護環境
  • 醫院和診所
  • 實驗室
  • 專科診所

13. 口服蛋白質和多肽市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章口服蛋白質和多肽市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。按國家/地區分類的口服蛋白質和胜肽市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • AbbVie Inc.
    • Amgen Inc.
    • Amryt Pharma plc
    • Astellas Pharma Inc.
    • AstraZeneca PLC
    • Biocon Limited
    • Boehringer Ingelheim International GmbH
    • Catalent, Inc.
    • Entera Bio Ltd. by DNA Biomedical Solutions
    • F. Hoffmann-La Roche AG
    • Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital
    • Johnson & Johnson Services, Inc.
    • Merck KGaA
    • Novartis AG
    • Novo Nordisk A/S
    • Oramed Pharmaceuticals Inc.
    • PeptiDream Inc.
    • Pfizer, Inc.
    • Protagonist Therapeutics, Inc.
    • Proxima Concepts Limited
    • Rani Therapeutics, LLC
    • Sanofi SA
    • Tarsa Therapeutics, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Zealand Pharma A/S
Product Code: MRR-036C5CF3B4AA

The Oral Proteins & Peptides Market is projected to grow by USD 19.21 billion at a CAGR of 13.67% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.89 billion
Estimated Year [2025] USD 7.78 billion
Forecast Year [2032] USD 19.21 billion
CAGR (%) 13.67%

A comprehensive orientation to how oral protein and peptide therapeutics are redefining clinical delivery models and commercial strategies across healthcare systems

Oral delivery of proteins and peptides represents a pivotal evolution in therapeutic modalities, reshaping how clinicians, patients, and industry stakeholders conceive of biologic treatment pathways. Recent technological advances have transformed molecules that were once strictly injectable into candidates for oral administration by addressing barriers such as enzymatic degradation, epithelial permeability, and inconsistent bioavailability. Consequently, developers have pursued a range of formulation strategies and delivery platforms that converge across chemistry, device engineering, and formulation science to unlock patient-preferred routes of administration and broaden the therapeutic footprint of biologics.

As the landscape matures, regulatory authorities and payers are increasingly attuned to the differentiated value propositions that oral proteins and peptides bring to chronic disease management, oncology supportive care, and hormonal therapies. This shift influences investment priorities, partnership strategies, and clinical development pathways. Importantly, the clinical and commercial potential hinges not only on molecular innovation but also on scalable manufacturing, validated pharmacokinetic performance, and reproducible real-world adherence outcomes. Taken together, these elements define a complex ecosystem in which scientific promise must align with commercial feasibility.

This executive summary synthesizes strategic inflection points, segmentation-driven insights, regional dynamics, corporate approaches, and pragmatic recommendations to guide leaders who must make time-sensitive decisions about pipeline prioritization, channel development, and manufacturing footprints. By focusing on actionable intelligence and rigorous methodological transparency, the analysis supports stakeholders seeking to navigate regulatory complexity, optimize product portfolios, and accelerate patient access across diverse care settings.

High-impact scientific, regulatory, and commercial inflection points that are accelerating the transition of injectable biologics to patient-preferred oral formats

The landscape for orally delivered proteins and peptides is undergoing a set of transformative shifts driven by converging scientific, regulatory, and commercial forces. First, advances in absorption enhancers, protease inhibitors, and carrier technologies have materially improved oral bioavailability for select peptide classes, enabling molecules previously constrained to parenteral routes to be reimagined for oral dosing. Alongside formulation chemistry, progress in enteric coatings and nanoparticulate systems has enhanced stability through the gastrointestinal tract, thereby increasing the feasibility of chronic oral regimens.

Simultaneously, regulatory frameworks are evolving to accommodate novel modalities and combination products. Regulatory agencies are clarifying pathways for demonstrating bioequivalence, safety margins, and device-drug co-development, which reduces uncertainty for sponsors and accelerates development timelines when aligned early. Payer conversations are also intensifying around the long-term value delivered by oral biologics, particularly when oral dosing demonstrably improves adherence, reduces clinic visits, and mitigates injection-related adverse events.

Commercially, stakeholder expectations are shifting. Patients and providers increasingly prioritize convenience and quality of life, while health systems scrutinize total cost of care. These drivers incentivize strategic partnerships between specialty biotechnology firms, contract development and manufacturing organizations, and the larger pharmaceutical ecosystem to bridge capabilities in clinical development, scalable manufacturing, and global distribution. Finally, the competitive landscape is being reshaped by the emergence of oral formulations targeting chronic indications, where the potential for broad uptake is high and where effective patient support programs and channel strategies will determine winner-take-share dynamics.

How trade policy shifts implemented in 2025 catalyzed supply chain reconfiguration, sourcing diversification, and strategic contracting across the oral biologics value chain

Trade policy adjustments enacted in 2025 introduced a new layer of operational and strategic complexity for manufacturers and distributors engaged in oral proteins and peptides. Tariff changes altered landed costs across critical inputs including excipients, advanced formulation components, and specialized packaging materials. As a consequence, procurement strategies shifted to prioritize supplier diversification and regional sourcing to reduce exposure to single-country tariffs and mitigate volatility in input pricing.

Manufacturers responded by reassessing global manufacturing footprints and accelerating conversations about nearshoring and multi-site redundancy. These decisions were influenced not only by cost considerations but also by lead-time reliability, regulatory harmonization across jurisdictions, and the need to preserve uninterrupted supply for chronic therapies. Contract manufacturing organizations experienced renewed demand as companies sought flexible capacity that could be deployed across geographies without triggering additional trade frictions.

In parallel, the tariff environment influenced partnership structures and commercial contracting. Organizations increasingly embedded tariff contingencies into supplier contracts and pricing models, and some adopted hedging strategies that insulated margins from short-term trade disruptions. Payers and integrated delivery networks also recalibrated procurement expectations, anticipating potential price pass-through effects and seeking risk-sharing arrangements that stabilized access for patients.

Importantly, the tariffs accelerated investment in component standardization and process optimization to reduce cost per dose and strengthen supply chain resilience. R&D budgets were rebalanced in some organizations to prioritize process intensification and formulation robustness, thereby reducing dependence on scarce or tariff-sensitive inputs. Overall, the cumulative impact of tariff policy in 2025 catalyzed strategic moves toward supply chain agility, collaborative manufacturing models, and contract structures designed to preserve market access and pricing stability in a more uncertain trade environment.

A segmentation-driven framework that connects product types, formulation choices, clinical development stages, therapeutic applications, and end-user channels to strategic decision-making

Insightful segmentation illuminates where scientific advances and commercial opportunities intersect, enabling leaders to align investments and development priorities with patient needs and canal feasibility. Based on product type, the market divides into insulin-based proteins and peptide therapeutics. The insulin-based proteins category includes combination insulin products, long-acting insulin analogues, rapid-acting insulin analogues, and recombinant human insulin, each presenting distinct formulation and delivery challenges tied to enzymatic stability and absorption kinetics. The peptide therapeutics category encompasses calcitonin-based therapies, glucagon-like peptide-1 receptor agonists, and vasopressin analogs, where molecular size, receptor pharmacology, and target indication shape feasibility for oral administration.

Based on formulation, the market spans capsule formulations, liquid formulations, powder formulations, and tablet formulations, and each format imposes trade-offs between stability, dose uniformity, manufacturability, and patient convenience. Developers must evaluate these trade-offs in the context of intended dosing frequency, target population, and distribution model. Based on development stage, the market includes Phase I & II clinical trials, Phase III clinical trials, post-market surveillance, and preclinical studies, reflecting a continuum where translational hurdles at early stages can materially affect later-stage commercialization pathways and risk profiles.

Based on application, the market targets cancer treatment, cardiovascular diseases, diabetes management, and hormonal disorders, with each therapeutic area presenting unique regulatory expectations, clinical endpoints, and payer evidence requirements. Developers should tailor clinical programs and value dossiers to the specific evidentiary demands of these indications. Based on end-user, the market serves home care settings, hospitals and clinics, research laboratories, and specialty clinics, which influences distribution strategies, patient support programs, and device design considerations to ensure adherence and patient safety outside traditional clinical settings.

Integrating segmentation perspectives highlights that portfolio decisions cannot be made in isolation; product type dictates formulation feasibility, while development stage dictates evidentiary requirements and time to access. Applications determine payer dialogue and clinical endpoint selection, and end-user considerations drive packaging, patient support, and distribution models. Leaders must therefore apply segmentation-driven lenses to align R&D, manufacturing, regulatory, and commercial teams toward coherent product strategies.

Strategic regional dynamics and go-to-market nuances across the Americas, Europe Middle East and Africa, and Asia-Pacific that determine access and scale for oral biologics

Regional dynamics shape the clinical trial landscape, manufacturing priorities, regulatory interactions, and commercialization strategies for oral proteins and peptides, and understanding these contours is essential for effective market entry. In the Americas, innovation hubs and integrated health systems create fertile conditions for early adoption of patient-centric delivery models, while established regulatory pathways offer predictable interactions but also require comprehensive real-world evidence to support broad reimbursement. As a result, companies often pilot adherence programs and value-based contracting frameworks in this region to demonstrate downstream cost offsets and improved outcomes.

In Europe, Middle East & Africa, heterogeneous regulatory environments and varied payer architectures necessitate differentiated market access strategies. This region demands adaptive regulatory engagement, selective country launches informed by local clinical practice patterns, and partnership approaches that leverage regional manufacturing or distribution partners to navigate importation and reimbursement complexity. Moreover, public health priorities and procurement frameworks can accelerate uptake in settings where oral delivery reduces clinic burden and supports decentralized care.

In the Asia-Pacific region, rapid adoption of novel therapeutics, strong manufacturing capacity, and growing local biotech ecosystems make it an important theater for both clinical development and scaled manufacturing. Regulatory authorities across the region are increasingly open to innovative trial designs and collaborative review processes, yet local market dynamics such as pricing pressure and competitive generics markets influence commercialization tactics. Consequently, strategic entry often combines clinical partnerships, local manufacturing or tolling arrangements, and tailored patient support programs that reflect regional care delivery models and payer expectations.

Collectively, regional insights underscore the need for geographically nuanced strategies that balance global regulatory alignment with local commercialization realities. Organizations that tailor their clinical programs, supply chain architecture, and reimbursement engagement to the specific characteristics of each region will be better positioned to convert clinical innovation into sustained patient access.

How corporate strategies, partnerships, and operational choices are aligning to derisk development and accelerate commercialization of oral peptide and protein therapeutics

Companies operating in the oral proteins and peptides domain are pursuing diverse strategies to de-risk development and accelerate commercialization. Some firms concentrate on proprietary formulation platforms that enable oral bioavailability across multiple peptide classes and therefore pursue licensing and platform partnerships to monetize their technology. Others prioritize tight integration of clinical and manufacturing capabilities to ensure a seamless path from early-phase demonstration of pharmacokinetics to scale-up for commercial production. Across the ecosystem, collaboration with contract development and manufacturing organizations has emerged as a common strategy to secure flexible capacity without incurring large capital expenditures.

Strategic alliances extend beyond manufacturing to include distribution partners, specialty pharmacies, and digital therapeutics vendors that can bolster adherence and real-world monitoring. Companies are also investing in evidence generation that aligns with payer value frameworks, including longitudinal adherence studies, health economics analyses, and comparator trials that highlight differential benefits of oral administration. In parallel, some organizations direct resources to improving supply chain resilience through multi-sourcing strategies and qualification of alternate excipient suppliers to mitigate disruption risk.

R&D pipelines reflect a spectrum of focus areas, from insulin analogues repurposed for oral dosing to peptide receptor agonists aimed at chronic metabolic and cardiovascular indications. Firms that pair robust clinical development programs with early payer engagement and clear manufacturing scale plans tend to accelerate path-to-reimbursement and market uptake. Finally, leadership teams are increasingly emphasizing regulatory foresight, embedding regulatory science expertise early in development to navigate combination product pathways, bioavailability challenges, and post-market surveillance obligations that accompany novel oral biologic formulations.

Actionable strategic priorities and operational levers that leaders must implement to convert oral biologic innovation into enduring commercial success

Industry leaders should prioritize a set of actionable steps that convert technical promise into sustainable commercial performance. First, integrate formulation and device development with early clinical trial design to ensure that pharmacokinetic and adherence objectives are embedded into pivotal study endpoints. This alignment reduces development iterations and improves the evidentiary continuity payers expect when assessing comparative value. Second, institutionalize supply chain resilience through supplier diversification, qualification of regional manufacturing partners, and modular production strategies that allow capacity redeployment as market demand evolves.

Third, begin payer and health system engagement early, using real-world demonstration projects to quantify adherence benefits and downstream resource offsets attributable to oral delivery. Early value conversations will smooth market access pathways and inform pricing strategies that reflect total cost of care. Fourth, structure partnerships that complement internal capabilities rather than duplicate them; selective licensing of platform technologies or co-development arrangements with established formulation specialists can accelerate timelines while preserving strategic control over core assets.

Fifth, invest in post-market evidence platforms that capture adherence, patient-reported outcomes, and pharmacovigilance data in decentralized settings. Such investments will support regulatory commitments and enrich the value proposition presented to payers and providers. Finally, adopt a staged regional deployment strategy that sequences launches to balance regulatory complexity, manufacturing capacity, and commercial readiness, thereby protecting margins while maximizing learnings for subsequent market entries.

A transparent mixed-methods research approach combining expert interviews, cross-functional workshops, and scenario analysis to ensure actionable and defensible insights

This analysis synthesizes primary and secondary research conducted under rigorous methodological standards to ensure reproducibility and strategic relevance. The research approach combined structured interviews with subject matter experts across formulation science, clinical development, regulatory affairs, manufacturing, and commercial operations. These qualitative insights were triangulated with publicly available regulatory guidance, peer-reviewed literature, and company disclosures to validate technical claims and infer likely industry responses to policy shifts.

Analytical methods included cross-functional workshops to map value chain dependencies, scenario planning to assess the impact of trade and regulatory volatility, and comparative case analyses of oral formulation programs across therapeutic areas. Where appropriate, assumptions were stress-tested through sensitivity analyses focused on key development and supply chain variables such as formulation success probability, manufacturing lead times, and post-approval surveillance requirements. The study also incorporated a limitations section that explicitly acknowledges areas of residual uncertainty, including long-term adherence behavior in real-world settings and evolving regulatory interpretations for novel delivery technologies.

Ethical protocols guided all primary research, ensuring informed consent, confidentiality, and the anonymization of proprietary insights. Finally, findings were peer-reviewed internally by multidisciplinary experts to ensure analytic rigor and practical applicability for stakeholders considering investments, partnerships, or portfolio reprioritization in oral proteins and peptides.

Concise synthesis of why integrated scientific, operational, and commercial alignment is essential for realizing the clinical and economic promise of oral biologic therapies

Oral proteins and peptides are moving from conceptual promise toward tangible clinical and commercial reality, propelled by advances in formulation science, shifting regulatory clarity, and evolving patient and payer expectations. These dynamics create a fertile environment for innovation but also impose new demands on organizational agility, supply chain design, and evidence generation. Success will favor organizations that integrate cross-disciplinary expertise early, structure partnerships to fill capability gaps, and align development strategies with pragmatic market access planning.

The interplay between product type, formulation path, development stage, application area, and end-user setting underscores the importance of segmentation-aware decision-making. Regional nuances further compel tailored strategies that balance global ambitions with local operational readiness. Importantly, recent trade policy adjustments have underscored the fragility of input-dependent value chains, accelerating moves toward diversified sourcing and regional capacity.

In sum, stakeholders who adopt an integrated approach-one that synchronizes scientific validation, manufacturing scalability, regulatory foresight, and payer-focused evidence development-will be best positioned to translate oral biologic advances into improved patient outcomes and durable commercial performance. The imperative now is to act with speed, precision, and collaborative intent to capture the window of opportunity that this therapeutic evolution presents.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in lipidation and PEGylation techniques to enhance oral peptide stability and bioavailability
  • 5.2. Integration of next generation permeation enhancers to facilitate transcellular transport of oral protein drugs
  • 5.3. Development of self-emulsifying drug delivery systems for oral insulin and GLP-1 analogues in diabetic therapy
  • 5.4. Adoption of novel protease inhibitors in formulation design to protect therapeutic peptides from gastrointestinal degradation
  • 5.5. Emerging use of microbiome-targeted peptide therapeutics to modulate gut flora and improve oral drug efficacy
  • 5.6. Strategic partnerships between biotech and pharmaceutical firms to accelerate commercialization of oral peptide vaccines and therapies
  • 5.7. Regulatory harmonization efforts in the US and EU driving streamlined approval pathways for oral peptide drug candidates
  • 5.8. Application of AI-driven peptide engineering platforms to optimize oral bioavailability and reduce development timelines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oral Proteins & Peptides Market, by Product Type

  • 8.1. Insulin-Based Proteins
    • 8.1.1. Combination Insulin Products
    • 8.1.2. Long-Acting Insulin Analogues
    • 8.1.3. Rapid-Acting Insulin Analogues
    • 8.1.4. Recombinant Human Insulin
  • 8.2. Peptide Therapeutics
    • 8.2.1. Calcitonin-Based Therapies
    • 8.2.2. Glucagon-Like Peptide-1 Receptor Agonists
    • 8.2.3. Vasopressin Analogs

9. Oral Proteins & Peptides Market, by Formulation

  • 9.1. Capsule Formulations
  • 9.2. Liquid Formulations
  • 9.3. Powder Formulations
  • 9.4. Tablet Formulations

10. Oral Proteins & Peptides Market, by Development Stage

  • 10.1. Phase I & II Clinical Trials
  • 10.2. Phase III Clinical Trials
  • 10.3. Post-Market Surveillance
  • 10.4. Preclinical Studies

11. Oral Proteins & Peptides Market, by Application

  • 11.1. Cancer Treatment
  • 11.2. Cardiovascular Diseases
  • 11.3. Diabetes Management
  • 11.4. Hormonal Disorders

12. Oral Proteins & Peptides Market, by End-User

  • 12.1. Home Care Settings
  • 12.2. Hospitals & Clinics
  • 12.3. Research Laboratories
  • 12.4. Specialty Clinics

13. Oral Proteins & Peptides Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Oral Proteins & Peptides Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Oral Proteins & Peptides Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AbbVie Inc.
    • 16.3.2. Amgen Inc.
    • 16.3.3. Amryt Pharma plc
    • 16.3.4. Astellas Pharma Inc.
    • 16.3.5. AstraZeneca PLC
    • 16.3.6. Biocon Limited
    • 16.3.7. Boehringer Ingelheim International GmbH
    • 16.3.8. Catalent, Inc.
    • 16.3.9. Entera Bio Ltd. by DNA Biomedical Solutions
    • 16.3.10. F. Hoffmann-La Roche AG
    • 16.3.11. Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital
    • 16.3.12. Johnson & Johnson Services, Inc.
    • 16.3.13. Merck KGaA
    • 16.3.14. Novartis AG
    • 16.3.15. Novo Nordisk A/S
    • 16.3.16. Oramed Pharmaceuticals Inc.
    • 16.3.17. PeptiDream Inc.
    • 16.3.18. Pfizer, Inc.
    • 16.3.19. Protagonist Therapeutics, Inc.
    • 16.3.20. Proxima Concepts Limited
    • 16.3.21. Rani Therapeutics, LLC
    • 16.3.22. Sanofi S.A.
    • 16.3.23. Tarsa Therapeutics, Inc.
    • 16.3.24. Teva Pharmaceutical Industries Ltd.
    • 16.3.25. Zealand Pharma A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ORAL PROTEINS & PEPTIDES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ORAL PROTEINS & PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ORAL PROTEINS & PEPTIDES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COMBINATION INSULIN PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COMBINATION INSULIN PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COMBINATION INSULIN PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COMBINATION INSULIN PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COMBINATION INSULIN PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COMBINATION INSULIN PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LONG-ACTING INSULIN ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LONG-ACTING INSULIN ANALOGUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LONG-ACTING INSULIN ANALOGUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LONG-ACTING INSULIN ANALOGUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LONG-ACTING INSULIN ANALOGUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LONG-ACTING INSULIN ANALOGUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RAPID-ACTING INSULIN ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RAPID-ACTING INSULIN ANALOGUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RAPID-ACTING INSULIN ANALOGUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RAPID-ACTING INSULIN ANALOGUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RAPID-ACTING INSULIN ANALOGUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RAPID-ACTING INSULIN ANALOGUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RECOMBINANT HUMAN INSULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RECOMBINANT HUMAN INSULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RECOMBINANT HUMAN INSULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RECOMBINANT HUMAN INSULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RECOMBINANT HUMAN INSULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RECOMBINANT HUMAN INSULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CALCITONIN-BASED THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CALCITONIN-BASED THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CALCITONIN-BASED THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CALCITONIN-BASED THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CALCITONIN-BASED THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CALCITONIN-BASED THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY VASOPRESSIN ANALOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY VASOPRESSIN ANALOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY VASOPRESSIN ANALOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY VASOPRESSIN ANALOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY VASOPRESSIN ANALOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY VASOPRESSIN ANALOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CAPSULE FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CAPSULE FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CAPSULE FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CAPSULE FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CAPSULE FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CAPSULE FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LIQUID FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LIQUID FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LIQUID FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LIQUID FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POWDER FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POWDER FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POWDER FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POWDER FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POWDER FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POWDER FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY TABLET FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY TABLET FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY TABLET FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY TABLET FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY TABLET FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY TABLET FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE I & II CLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE I & II CLINICAL TRIALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE I & II CLINICAL TRIALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE I & II CLINICAL TRIALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE I & II CLINICAL TRIALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE I & II CLINICAL TRIALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POST-MARKET SURVEILLANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POST-MARKET SURVEILLANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POST-MARKET SURVEILLANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POST-MARKET SURVEILLANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POST-MARKET SURVEILLANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POST-MARKET SURVEILLANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRECLINICAL STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRECLINICAL STUDIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRECLINICAL STUDIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRECLINICAL STUDIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRECLINICAL STUDIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRECLINICAL STUDIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CANCER TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CANCER TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CANCER TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CANCER TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HORMONAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HORMONAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HORMONAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HORMONAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC ORAL